Endoscopic incisional balloon dilation combined with anti-scarring agents for postoperative esophageal anastomotic strictures.

The management of locally advanced esophageal cancer typically involves esophagectomy; however, postoperative complications, particularly anastomotic stricture, remain prevalent. Anastomotic stricture can severely compromise patients' quality of life by leading to difficulties in food intake. Although endoscopic balloon dilation has become a standard treatment for gastrointestinal strictures, its efficacy is often limited due to the risk of perforation and the potential for recurrent stricture, necessitating multiple interventions.

From Coronavirus Disease 2019 to Herpes Simplex Virus Hepatitis: A Case Report of Complications Linked to Immunosuppressive Therapy.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been linked to severe pneumonia and systemic deterioration in humans. When antiviral drugs and antibodies are not available, it is preferable to choose early treatment methods to suppress cytokine storms. While an interleukin-6 receptor antagonist has proven effective in controlling cytokine storms in coronavirus disease 2019 (COVID-19) pneumonia, it can also increase susceptibility to secondary infections, such as herpes simplex virus (HSV).

Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning.

Background: Pancreatic cancer is often diagnosed at advanced stages, and early-stage diagnosis of pancreatic cancer is difficult because of nonspecific symptoms and lack of available biomarkers.

Methods: We performed comprehensive serum miRNA sequencing of 212 pancreatic cancer patient samples from 14 hospitals and 213 non-cancerous healthy control samples. We randomly classified the pancreatic cancer and control samples into two cohorts: a training cohort (N = 185) and a validation cohort (N = 240).

Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.

To quantify the clinical unmet need of r/r MCL patients who progress on a covalent Bruton tyrosine kinase inhibitor (BTKi), we conducted a systematic review to identify studies that reported overall survival (OS), progression-free survival (PFS), or response outcomes of patients who received a chemo(immunotherapy) ± targeted agent standard therapy (STx) or brexucabtagene autoleucel (brexu-cel) in the post-BTKi setting. Twenty-six studies (23 observational; three trials) reporting outcomes from 2005 to 2022 were included. Using two-stage frequentist meta-analyses, the estimated median PFS/OS for patients treated with an STx was 7.